Thank you. Operator, and welcome to the presentation of Bactiguard. Bactiguard's fourth quarter, as well as the full year 2025. Our CFO, Patrick Bach, and I will go through the presentation together. And at the end, there will be time for your questions.
Let's start with some high-level comments on the quarter and summarize 2025. Patrick will go into more details on the financials later in the presentation. We closed the year with a great Q4.
Total revenues increased by more than 4% when excluding the negative effect of currency. Given our substantial US dollar exposure within the licensed business, the weaker dollar does continue to impact our revenues negatively. The main driver for both the fourth quarter and full year on revenues and EBITDA was the updated agreement with Zimmer Biomet in December. I will come back to how this new agreement reflects the solidified collaboration between Bactiguard and Zimmer Biomet.
A bit later, the strong finish resulted in stable license revenue for the full year, again excluding the currency impact. We achieved this despite the fact that the 2024 comparison year included exclusivity revenues from the now terminated agreement. Total revenue decreased in 2025, but thanks to our new cost base and continued cost discipline, EBITDA continued to improve in the year.
As we close out 2025, I would like to reflect on the strategic steps we have been taking throughout the year to advance our transition and shape the Bactiguard we are becoming. We are now a more focused and better aligned organization, with our operations increasingly structured to support our new business model. That said, we do remain in the midst of our transformation, and meaningful changes take time.
Let's review our progress in line with our strategic pillars; we have further strengthened our existing partnerships with both BD and Zimmer Biomet to advance licensed partnerships. We have refined our joint approach to collaboration and aligned our ways of working accordingly. I will explain more about each of these partnerships in more detail later. Development of new partnerships plays a key role in executing on our strategy. Our efforts have generated encouraging signals, and we have seen solid progress across an expanding range of early stage initiatives.
We have continued to invest in our key knowledge areas, with a particular focus on regulatory expertise related to the coating technology, as well as evaluation of new materials and applications. Continued data generation with Bactiguard technology is critical for market validation, and clinical studies in collaboration with our partners are proceeding according to plan in the Wound Management portfolio. Our strategic focus has been on Hydrocyn aqua, where we have strong growth. We see customer demand across the total portfolio and therefore include investments such as MDR regulatory transitions that will allow us to continue to drive stronger growth across product categories going forwards.
In our license business, we focus on therapeutic areas with meaningful infection rates, creating a critical unmet need for effective infection prevention solutions. Our selected strategic areas orthopedics, cardiology, neurology, urology, and vascular access are associated with infections that can lead to poor patient outcomes, severe complications, and in some cases, death, while also driving significant costs for health care. These areas offer the strongest potential for both enhanced and future licensing partnerships.
I previously highlighted our progress in business development, and I want to emphasize our broad pipeline of potential new licensing partners, now including, as of this past year, two additional therapeutic areas, cardiology and neurology, which we are exploring at new and highly relevant conferences. We have found great interest from companies with applications at risk for infection in these areas. For example, we recently attended NUNS, the North American Neuromodulation Society conference, and earlier TCT, a conference for interventional cardiology. While our discussions are still in an early stage, we have confirmed shared views of infection prevention relevance in key application areas across all of our therapeutic areas.
Even though we are very encouraged by the early stage testing currently underway, it is important to emphasize that bringing MedTech innovations to market is a long-term process, typically taking several years from initial testing to commercialization.
These initial advances reinforce our confidence in the future value that can be created by leveraging our technology.
If we dive into our commercial stage partnership with BD, the collaboration has advanced steadily throughout the year. We continue to support the market transition throughout the value chain, for example through technology training for distributors and joint participation in conferences and sales activities. This particular photo with both Bactiguard and BD representatives, was taken at the Swedish Urology Conference of the Swedish Urological Association and the National Association for Urology Nurses in early October in India, where we have previously marketed our own catheters. BD launched its Bactiguard coated catheters earlier this year. The Indian market offers significant potential due to major challenges with healthcare-associated infections, and we continue to support market penetration there.
At the same time, we are preparing for other upcoming market transitions. At the end of last year, BD received its CE mark that enables additional launches, including in the European market. We remain fully aligned with BD on jointly driving growth of the Bactiguard coated Foley catheters business.
As stated before, our extraordinary Q4 results were primarily driven by the updated Trauma License agreement with Zimmer Biomet. The update, signed in December, reflects the mutual understanding to align our contracts around the ZNN Bactiguard coated trauma nail system and to reflect the ongoing or imminent market activities. This outlines the current scope of our collaboration. I want to emphasize that this does not preclude our ability to collaborate outside the areas covered by the revised contract. However, advancing to a later stage in such processes will require additional agreements.
The updated license agreement now covers non-exclusive rights to Europe, selected markets in the Middle East and Africa, and Japan.
Bactiguard regained the remaining global rights and now has the ability to form future orthopaedic trauma partnerships, either with Zimmer or other companies under our newly re-cemented partnership. The commercialization of ZNN Bactiguard continues across Europe and in Middle East markets. Today, we have a strong relationship with Zimmer Biomet, supported by ways of working that foster our long-term collaboration.
The ZNN Bactiguard infection prevention solution remains a part of Zimmer Biomet Infection Management strategic pillar, and we continue to work jointly on post-market clinical trials and regulatory transitions from MDD to MDR to drive future growth.
Switching over to Wound Management through sales efforts and onboarding of new distributors in multiple markets, Hydrocyn continued to show double-digit growth across the product lines during 2025. This expansion was largely offset by a drop in revenues in sutures in specific markets. Looking ahead, we see customer demand across the total Wound Management portfolio, which means that we expect to drive stronger growth in all product categories within Wound Management going forward and in line with our longer term strategic targets here as well. MDD to MDR regulatory transitions and investments are underway to be able to scale the portfolio to meet the demand.
With that, I will hand over to you, Patrick, to review our Q4 and full year financial outcomes in more detail.